Volpé R
Department of Medicine, University of Toronto, Ontario, Canada.
Endocrinol Metab Clin North Am. 1991 Sep;20(3):565-87.
Considerable evidence for a genetically induced antigen-specific defect in suppressor T lymphocytes as the basis for AITD has been derived from several laboratories and via different types of experimental techniques. This defect may result from abnormal antigen presentation to T lymphocytes via an aberrant antigen-specific HLA-related gene. In addition, there is now evidence for additive effects on reducing generalized suppressor T lymphocyte numbers and function by environmental factors as well as hyperthyroidism itself. These effects would be superimposed on the organ-specific defect. Such effects on generalized suppressor T lymphocyte numbers may act as precipitating and self-perpetuating factors. Presentation of the antigen by the thyroid cell via HLA-DR expression on its cell membrane does occur as a result of IFN-gamma production by T lymphocytes. This appears to be secondary to the initial specific immune assault and is not a primary inductive step. Although it may be important as an amplifying intermediate factor, antigen presentation cannot perpetuate the process in the absence of the underlying immune disorder. There is, indeed, no evidence for an underlying antigenic abnormality or stimulus in human autoimmune thyroid disease, and the initiating event would appear to be due to perturbation of the generalized immune system superimposed on the organ-specific immunoregulatory abnormality. Variations in the serologic and clinical expression of AITD would appear to depend on the severity of the original organ-specific disturbance in suppressor T lymphocyte function, plus the added factor of environmental influences playing on generalized suppressor T lymphocyte function and numbers. Remissions in Graves' disease brought about by antithyroid drugs may well be via their effect on modulating thyroid cell activity; this then reduces thyrocyte-immunocyte signaling, allowing remission to occur in those patients with a partial organ-specific defect in suppressor T lymphocytes.
多个实验室通过不同类型的实验技术得出了大量证据,表明抑制性T淋巴细胞中存在基因诱导的抗原特异性缺陷是自身免疫性甲状腺疾病(AITD)的基础。这种缺陷可能是由于通过异常的抗原特异性HLA相关基因向T淋巴细胞呈递抗原异常所致。此外,现在有证据表明环境因素以及甲状腺功能亢进本身对降低全身性抑制性T淋巴细胞数量和功能具有累加效应。这些效应会叠加在器官特异性缺陷之上。对全身性抑制性T淋巴细胞数量的这种影响可能起到促发和自我延续的作用。T淋巴细胞产生的γ干扰素会导致甲状腺细胞通过其细胞膜上的HLA-DR表达来呈递抗原。这似乎是初始特异性免疫攻击的继发结果,而非主要的诱导步骤。尽管作为放大的中间因素可能很重要,但在没有潜在免疫紊乱的情况下,抗原呈递无法使这一过程持续下去。实际上,在人类自身免疫性甲状腺疾病中没有证据表明存在潜在的抗原异常或刺激,引发事件似乎是由于全身性免疫系统的扰动叠加在器官特异性免疫调节异常之上。AITD的血清学和临床表达差异似乎取决于抑制性T淋巴细胞功能最初的器官特异性紊乱的严重程度,再加上环境因素对全身性抑制性T淋巴细胞功能和数量的影响这一附加因素。抗甲状腺药物导致的格雷夫斯病缓解很可能是通过它们对调节甲状腺细胞活性的作用;这进而减少甲状腺细胞 - 免疫细胞信号传导,使那些抑制性T淋巴细胞存在部分器官特异性缺陷的患者得以缓解。